Alaunos Therapeutics Form 4: Vieser Adds Shares, Receives $5 Options

Rhea-AI Filing Summary

Form 4 highlights: Director Jaime Vieser received new equity awards from Alaunos Therapeutics (TCRT) on 07/03/2025.

• Restricted Stock Units (RSUs): 3,400 common shares granted and fully vested immediately. This raised Vieser’s directly held stock from 17,759 to 21,159 shares.
• Employee Stock Options: 6,400 options with a $5.00 exercise price and 07/03/2035 expiry. One-twelfth vests each month; any unvested balance vests immediately before the 2026 annual meeting.
• Total beneficial ownership after the grant: 21,159 shares held directly, 2,100 shares held indirectly through children, and 13,503 shares held indirectly via Brushwood LLC where Vieser is Manager.

The awards were issued at $0.00 cost for the RSUs and standard option pricing for the options, indicating compensation rather than an open-market purchase. While the absolute numbers are modest relative to typical public-company share counts, the filing shows continued equity-based alignment between the director and shareholders.

Positive

• Director’s direct shareholding rises 19% (to 21,159 shares), improving insider alignment.
• 6,400 new options at $5 strike create performance-based incentive extending to 2035.

Negative

• None.

Insights

Securities Analyst

TL;DR: Compensation grant; small insider ownership increase, neutral market impact.

The transaction is a routine board compensation event. Vieser’s additional 3,400 RSUs and 6,400 options marginally increase insider ownership but do not involve cash purchases, so they offer limited signalling power. The $5 strike is likely above the recent trading price, providing incentive alignment without immediate dilution. Aggregate ownership (≈36.8 k shares/options) remains immaterial to Alaunos’s outstanding float, suggesting low fundamental impact on valuation or near-term supply-demand dynamics.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vieser Jaime

(Last) (First) (Middle)

C/O ALAUNOS THERAPEUTICS, INC.

2617 BISSONNET ST, SUITE 233

(Street)

HOUSTON TX 770005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Alaunos Therapeutics, Inc. [ TCRT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/03/2025		A		3,400(1)	A	$0.00	21,159	D
Common Stock								2,100	I	by Reporter's children
Common Stock								13,503(2)	I	By Brushwood LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$5	07/03/2025		A		6,400		(3)	07/03/2035	Common Stock	6,400	$0.00	6,400	D

Explanation of Responses:

1. Represents a grant of restricted stock units (RSUs) which immediately vested upon grant. After the reported acquisition of the RSUs, the reporting person owned in aggregate 21,159 shares of common stock (17,759 previously owned shares, plus the instant grant of 3,400 RSUs).

2. The shares are directly held by Brushwood LLC. The Reporting Person is the Manager of Brushwood LLC.

3. One-twelfth of the Option vests each month on the monthly anniversary of July 3, 2025, with any amount that remains unvested on the date immediately preceding the Company's 2026 annual general meeting of stockholders vesting thereon.

	/s/ Melinda Lackey	07/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Alaunos Therapeutics (TCRT) shares did Jaime Vieser acquire?

Vieser received 3,400 fully-vested RSUs, raising direct ownership to 21,159 common shares.

What is the exercise price and term of the new options granted to the director?

The options cover 6,400 shares at a $5.00 exercise price and expire on 07/03/2035.

How does the option vesting schedule work?

One-twelfth of the grant vests monthly beginning 07/03/2025; any remainder vests right before the 2026 AGM.

Did the director purchase shares on the open market?

No. The Form 4 reports equity compensation grants (RSUs and options) issued at no cash cost.

What is Jaime Vieser’s total beneficial ownership after the filing?

Direct: 21,159 shares; Indirect: 2,100 shares (children) and 13,503 shares (Brushwood LLC).